High‐dose sinomenine attenuates ischemia/reperfusion‐induced hepatic inflammation and oxidative stress in rats with diabetes mellitus
Immunity, Inflammation and Disease · 2024
DOI: 10.1002/iid3.1271 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, 2024. Verfasst von Bo Hui und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery Unit-4, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Hauptthemen laut MEDLINE: Oxidative Stress, Morphinans, Diabetes Mellitus, Experimental, Reperfusion Injury. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Research and Development Project of Shaanxi Province.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
Ischemia‐reperfusion (I/R) injury, resulting from blood flow interruption and its subsequent restoration, is a prevalent complication in liver surgery. The liver, as a crucial organ for carbohydrate and lipid metabolism, exhibits decreased tolerance to hepatic I/R in patients with diabetes mellitus (DM), resulting in a significant increase in hepatic dysfunction following surgery. This may be attributed to elevated oxidative stress and inflammation. Our prior research established sinomenine's (SIN) protective role against hepatic I/R injury. Nevertheless, the impact of SIN on hepatic I/R injury in DM rats remains unexplored. Objective and Methods This study aimed to investigate the therapeutic potential of SIN in hepatic I/R injury in DM rats and elucidate its mechanism. Diabetic and hepatic I/R injury models were established in rats through high‐fat/sugar diet, streptozotocin injection, and hepatic blood flow occlusion. Liver function, oxidative stress, inflammatory reaction, histopathology, and Nrf‐2/HO‐1 signaling pathway were evaluated by using UV spectrophotometry, biochemical assays, enzyme‐linked immunosorbent assay, hematoxylin‐eosin staining, and Western blot analysis.
Results
High‐dose SIN (300 mg/kg) significantly attenuated hepatic I/R injury in DM rats, reducing serum activities of ALT and AST, decreasing the AST/ALT ratio, enhancing tissue contents of SOD and GSH‐Px, suppressing the levels of TNF‐α and IL‐6, improving the liver histopathology, and activating Nrf‐2/HO‐1 signaling by promoting Nrf‐2 trans‐location from cytoplasm to nucleus. Low‐dose SIN (100 mg/kg) was ineffective.
Conclusions
This study demonstrates that high‐dose sinomenine's mitigates hepatic I/R‐induced inflammation and oxidative stress in diabetes mellitus (DM) rats via Nrf‐2/HO‐1 activation, suggesting its potential as a preventive strategy for hepatic I/R injury in DM patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery Unit-4, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
ORCID-Profile: Zhengan Yang
Förderung
- Science and Technology Research and Development Project of Shaanxi Province
Zitieren
APA
Hui, B., Zhang, X., Dong, D., Shu, Y., Li, R., & Yang, Z. (2024). High‐dose sinomenine attenuates ischemia/reperfusion‐induced hepatic inflammation and oxidative stress in rats with diabetes mellitus. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.1271
Vancouver
Hui B, Zhang X, Dong D, Shu Y, Li R, Yang Z. High‐dose sinomenine attenuates ischemia/reperfusion‐induced hepatic inflammation and oxidative stress in rats with diabetes mellitus. Immunity, Inflammation and Disease. 2024. doi:10.1002/iid3.1271
BibTeX
@article{Hui2024,
author = {Hui, Bo and Zhang, Xiaogang and Dong, Dinghui and Shu, Yantao and Li, Ren and Yang, Zhengan},
title = {High‐dose sinomenine attenuates ischemia/reperfusion‐induced hepatic inflammation and oxidative stress in rats with diabetes mellitus},
journal = {Immunity, Inflammation and Disease},
year = {2024},
doi = {10.1002/iid3.1271}
}
EUVIMED